Skip to main content

Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients



Breast cancer (BC) represents one of the leading causes of cancer related deaths worldwide. New tools for diagnostic staging and therapeutic monitoring are needed to improve individualized therapies and improve clinical outcome. The analyses of circulating tumour cells may provide important prognostic information in the clinical setting.

Materials and methods

Circulating tumour cells (CTC) of 63 BC patients were isolated from peripheral blood (PB) through immunomagnetic separation. Subsequently, RT-PCR or mPCR for the genes ga733.2, muc-1, c-erbB2, mgb-1, spdef and c-erbB2 were performed. Subsequently, expression data were correlated with the tumour stages. Fourteen healthy individuals served as controls.


Significant correlations with tumour stages were found in single gene analyses of ga733.2, muc-1 and in multi-gene analyses of ga733.2/muc-1/mgb1/spdef. Furthermore, a significant correlation of Ca 15-3 and all studied genes was also observed.


Herein, we demonstrated a positive correlation of a gene signature consisting of ga733.2, muc-1, mgb1 and spdef and advanced stages of BC. Moreover, all studied genes and gene patterns revealed a significant correlation with Ca 15-3 positive cases.


Even though new developments in clinical research on breast cancer (BC) have provided clinicians with a set of important diagnostic tools, there is still an urgent need for further, more sensitive staging techniques. Recent studies have shown that quantitative and qualitative analyses of circulating tumour cells (CTC) may provide prognostic information in BC [1, 2]. Attempts to isolate CTC in peripheral blood (PB) date back to more than 100 years [3]. Sandberg et al. isolated CTC from BC patients using centrifugation and fibrinogen to aggregate erythrocytes [4]. Notably, Hsieh et al. reported that the absolute count of CTC may be related to an aggressive course of disease in BC patients [5]. First attempts to isolate CTC through immunomagnetic separation were made by Berois et al using a CK-19 on BC cell lines [6]. This technique was recently successfully used by Hardingham et al. in patients with gastrointestinal neoplasias [7]. Combining immunomagnectic separation and real-time-PCR (RT-PCR), this group could positively correlate the presence of CTC in PB with shorter disease-free intervals.

Gene profile analyses of certain putative genetic markers may lead to sensitive and specific CTC detection and may enable an improvement in the outcome prediction [813]. In fact, PCR and RT-PCR can be applied to perform expression analyses of immunomagnectically isolated CTC. In a previous study we analysed the CTC of 63 BC patients in various disease stages and identified the genes ga733.2, muc-1, mgb1 and spdef as putative markers for CTC detection. Based upon our previous data, in this study we performed correlation analyses between the detected gene expression levels and the known clinical staging of breast cancer. Furthermore, we compared the gene expression data with the detected Ca15-3 serum levels. Increased serum levels of the tumour marker Ca 15-3 have been associated with advanced disease and poor outcome in several studies [14, 15].

Materials and methods

Our study population consisted of 63 BC patients and 14 healthy controls. 50 patients with first diagnosed disease (FD) and 13 patients with metastatic disease (MD) in various disease stages were enrolled. All patients provided written informed consent. After peripheral venous blood sampling, CTC were separated using an immunomagnetic method (Adnagen Breast Cancer Select Kit) according to the instructions of the manufacturer (Adnagen). Cell lysates underwent mRNA isolation and reverse transcription following the manufacturer's instructions (Promega). Subsequently, mPCR for the genes ga733.2 and muc-1 and RT-PCRfor the genes mgb1 and spdef were performed. The resulting gene profiles were then compared with tumour stage according to the TNM grading system and tumour stage of the American Joint Committee on Cancer (AJCC) [16]. Additionally, CTC profiling was compared to ELISA-determined Ca 15-3 positivity. Correlations were performed either by Pearson's two-sided χ2-test for dichotomized values or by Pearson's bivariate correlation for values with two thresholds. Significance was defined by p < 0.05.


Correlation to disease state

Single gene expression and gene patterns were correlated to first diagnosed disease (FD) and metastatic disease (MD). Only mgb1 was significantly correlated to MD (p = 0.019) but not to FD, whereas spdef, muc-1, ga733.2 and c-erbB2 did not correlate with disease stage. Consecutive multiple gene evaluations demonstrated significance for the pattern ga733.2/muc-1 (p = 0.045). The gene pattern ga733.2/muc-1/spdef/mgb1 showed a significant correlation with MD (p = 0.023).

Correlation to tumour stage

Tumour stage was specified according to AJCC guidelines [16]. Since the tumour stage could not be identified in two BC cases, these patients were excluded from the study. Single positivity within the gene pattern ga733.2/muc-1 was significantly related to advanced disease, with 10 out of 12 positive cases found in level IIIa or higher. Similarly, 11 out of 15 single positive results within the gene pattern ga733.2/muc-1/mgb1/spdef were observed in level IIIa or higher. Finally, 90% (9 out of 10) of twofold-positive results within the 4 gene pattern were documented in higher levels (p = 0.001) (Table 1).

Table 1 Correlation to disease staging.

Correlation to nodal status

The gene expression profiles were further correlated with nodal status. Lymph node (N) status was not available in 4 patients. They were excluded from further analyses. N status was stratified in three levels, N0, N1 and ≥ N2. Significant correlation was found between ga733.2 (p = 0.042) and muc-1 (p = 0.039) overexpression and higher N-levels. The analyses of spdef, mgb1, ga733.2 and muc-1 did not reveal a significant correlation. Interestingly, two-fold positive results with in the gene pattern ga733.2/muc-1/mgb1/spdef were significant (p = 0.016), whereas simple positive results within this gene pattern did not correlate with nodal status (Table 2).

Table 2 Correlation to nodal status.

Correlation to distant metastases

Gene expression profiles were correlated with the presence of distant metastases. muc-1 overexpression was significantly related to metastatic disease (p = 0.025). Furthermore, 4 out of 5 patients overexpressing mgb1 presented with distant metastases (p = 0.018). Finally, the gene profiles ga733.2/muc-1 (p = 0.018) and ga733.2/muc-1/spdef/mgb1 (p = 0.046) significantly correlated with advanced disease (Table 3).

Table 3 Correlation to distant metastases.

Correlation to Ca 15-3 status

The gene expression data were also compared with ELISA-determined Ca 15-3 serum levels. Ca 15-3 could not be determined in 4 cases. Positive single gene and gene pattern strongly correlated with Ca 15-3 positive cases. Statistical analyses revealed highly-significant results for all genes and gene patterns (Table 4).

Table 4 Correlation to Ca 15-3.


Haematological dissemination of malignant cells is a prerequisite to distant organ metastases in many cancer entities [2124]. Yet, several studies suggest that only a minority of tumour cells have the ability to invade and metastasize [1719]. Therefore, it is crucial to investigate which genes ultimately facilitate tissue invasion and disease progression.

Here, we propose an association between a certain set of genes (ga733.2, muc-1, mgb1 and spdef) and advanced tumour stages in BC. Notably, the studied gene signature exposed a significant correlation with stage levels IIIa or higher. Herein, muc-1 expression significantly correlated with nodal and distant metastases, and hence higher staging levels. In line with these results, it has been recently shown that a muc-1-induced tumourigenesis gene signature could predict disease-free and overall survival in patients with breast and lung cancer [20].

All investigated genes and gene profiles were significantly correlated with Ca 15-3 positivity. Since elevated levels of this tumour marker have been shown to predict the outcome in BC, the gene signature we analyzed is likely to hold prognostic relevance.

The present investigation poses several questions: First, since the analyses was not performed in a prospective manner, it is impossible to determine whether the detected gene profiles in patients with late disease might also be present in early stages of the disease. Second, it remains to be studied whether CTC exhibit a daily or hourly fluctuation in the gene expression levels. This could lead to false negative results in the proposed method.

In summary, our data indicate a notable correlation between the studied genes (ga733.2, muc-1, mgb1 and spdef) and advanced disease in BC. Accordingly, the studied genes might play a role in the process of metastases formation. However, prospective studies in a larger patient population are needed to further validate the proposed hypothesis.



breast cancer


circulating tumour cells


peripheral blood

c-erbB2 :

cellular avian erythroblastosis homologue B2

ga733.2 :

major gastrointestinal tumour-associated protein

muc-1 :


mgb-1 :



messenger RNA


polymerase chain reaction


reverse transcriptase polymerase chain reaction


reverse transcriptase

spdef :

SAM pointed domain- containing ETS transcription factor


First Diagnosis


Metastatic disease.


  1. 1.

    Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H: Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res 2009,28(1):57. 10.1186/1756-9966-28-57

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  2. 2.

    Cristofanilli M, Hayes DF, Budd GT, et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23: 1420–30. 10.1200/JCO.2005.08.140

    PubMed  Article  Google Scholar 

  3. 3.

    Ashworth TR: A Case of Cancer in which cells similar to those in the tumors were seen in the blood after death. Australian Medl J 1869, 146–148.

    Google Scholar 

  4. 4.

    Sandberg AA, Moore GE: Examination of blood for tumor cells. J Natl Cancer Inst 1957,19(1):1–11.

    CAS  PubMed  Google Scholar 

  5. 5.

    Hsieh HB, Marrinucci D, Bethel K, et al.: High speed detection of circulating tumor cells. Biosens Bioelectron 2006, (21):1893–9.

  6. 6.

    Berois N, et al.: Detection of rare human breast cancer cells. Comparison of an immunomagnetic separation method with immunocytochemistry and RT-PCR. Anticancer Res 1997,17(4A):2639–46.

    CAS  PubMed  Google Scholar 

  7. 7.

    Hardingham JE, et al.: Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 2000,89(1):8–13. 10.1002/(SICI)1097-0215(20000120)89:1<8::AID-IJC2>3.0.CO;2-K

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994, 14: 7068–77.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. 9.

    Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999, 27: 4008–17. 10.1093/nar/27.20.4008

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  10. 10.

    Siegel PM, Ryan ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. Embo J 1999, 18: 2149–64. 10.1093/emboj/18.8.2149

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  11. 11.

    Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al.: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990, 265: 15286–93.

    CAS  PubMed  Google Scholar 

  12. 12.

    Eltahir EM, Mallinson DS, Birnie GD, Hagan C, George WD, Purushotham AD: Putative markers for the detection of breast carcinoma cells in blood. Br J Cancer 1998, 77: 1203–7. 10.1038/bjc.1998.203

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  13. 13.

    Lambrechts AC, van't Veer LJ, Rodenhuis S: The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol 1998, 9: 1269–76. 10.1023/A:1008445604263

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D: Clinical value of Ca 15–3, mucinlike carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996,19(5):459–64. 10.1097/00000421-199610000-00007

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS: Preoperative Ca 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008,19(4):675–81.

    PubMed  Article  Google Scholar 

  16. 16.

    Greene PDFL, Fleming ID, et al.: AJCC Cancer Staging Manual. 6th edition. New York: Springer; 2002.

    Google Scholar 

  17. 17.

    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003,100(7):3983–8. 10.1073/pnas.0530291100

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  18. 18.

    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994,367(6464):645–8. 10.1038/367645a0

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001,414(6859):105–11. 10.1038/35102167

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR: MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009,69(7):2833–7. 10.1158/0008-5472.CAN-08-4513

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  21. 21.

    Bölke E, Peiper M, Budach W, Matuschek C, Schwarz A, Orth K, Gripp S: Unilateral keloid formation after bilateral breast surgery and unilateral radiation. Eur J Med Res 2007, 12: 320–322.

    PubMed  Google Scholar 

  22. 22.

    Matthaei H, Boelke E, Eisenberger CF, Alldinger I, Krieg A, Schmelzle M, Poremba C, Schellhammer F, Knoefel WT, Budach W, Peiper M: Interdisciplinary treatment of primary hepatic angiosarcoma: emergency tumor embolization followed by elective surgery. Eur J Med Res 2008, 4: 591–594.

    Google Scholar 

  23. 23.

    Matthaei H, Bölke E, Schmelzle M, Budach W, Orth K, Engers R, Cohnen M, Matuschek C, Gripp S, Knoefel WT, Peiper M: Modern therapy of rectal carcinoma. Eur J Med Res 2008, 13: 139–146.

    CAS  PubMed  Google Scholar 

  24. 24.

    Peiper M, Bölke E, Orth K, Hosch SB, Rehders A, Matthaei A, Knoefel WT: Current status of radical systematic lymphadenectomy in pancreatic cancer review of the literature. Eur J Med Res 2007, 12: 1–7.

    Google Scholar 

Download references


This work is dedicated to Kim and Thomas Speer. Furthermore this work is a part of the thesis of Burak Dogan

Author information



Corresponding author

Correspondence to H Bojar.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bölke, E., Orth, K., Gerber, P. et al. Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients. Eur J Med Res 14, 359 (2009).

Download citation


  • Mamma carcinoma
  • gene signature
  • real-time-PCR